JP2019531705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531705A5 JP2019531705A5 JP2019505188A JP2019505188A JP2019531705A5 JP 2019531705 A5 JP2019531705 A5 JP 2019531705A5 JP 2019505188 A JP2019505188 A JP 2019505188A JP 2019505188 A JP2019505188 A JP 2019505188A JP 2019531705 A5 JP2019531705 A5 JP 2019531705A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- less
- mutation
- compared
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 154
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 154
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 154
- 230000035772 mutation Effects 0.000 claims description 87
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 21
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 10
- 238000000423 cell based assay Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 8
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 8
- 239000012636 effector Substances 0.000 claims description 8
- 230000006870 function Effects 0.000 claims description 8
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 102100023431 E3 ubiquitin-protein ligase TRIM21 Human genes 0.000 claims description 6
- 101000685877 Homo sapiens E3 ubiquitin-protein ligase TRIM21 Proteins 0.000 claims description 6
- 108010073807 IgG Receptors Proteins 0.000 claims description 6
- 102000009490 IgG Receptors Human genes 0.000 claims description 6
- 230000008827 biological function Effects 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000001393 triammonium citrate Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 4
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 4
- 206010057249 Phagocytosis Diseases 0.000 claims description 4
- 239000001825 Polyoxyethene (8) stearate Substances 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000008782 phagocytosis Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 238000006386 neutralization reaction Methods 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 238000010171 animal model Methods 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 230000001447 compensatory effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 2
- 230000031998 transcytosis Effects 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022096036A JP2022120132A (ja) | 2016-08-02 | 2022-06-14 | 操作されたポリペプチドおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370201P | 2016-08-02 | 2016-08-02 | |
| US62/370,201 | 2016-08-02 | ||
| US201762485671P | 2017-04-14 | 2017-04-14 | |
| US62/485,671 | 2017-04-14 | ||
| PCT/US2017/045126 WO2018052556A1 (en) | 2016-08-02 | 2017-08-02 | Engineered polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096036A Division JP2022120132A (ja) | 2016-08-02 | 2022-06-14 | 操作されたポリペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531705A JP2019531705A (ja) | 2019-11-07 |
| JP2019531705A5 true JP2019531705A5 (https=) | 2020-09-10 |
| JP7464389B2 JP7464389B2 (ja) | 2024-04-09 |
Family
ID=59656189
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505188A Active JP7464389B2 (ja) | 2016-08-02 | 2017-08-02 | 操作されたポリペプチドおよびその使用 |
| JP2022096036A Withdrawn JP2022120132A (ja) | 2016-08-02 | 2022-06-14 | 操作されたポリペプチドおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096036A Withdrawn JP2022120132A (ja) | 2016-08-02 | 2022-06-14 | 操作されたポリペプチドおよびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11858980B2 (https=) |
| EP (1) | EP3494134B1 (https=) |
| JP (2) | JP7464389B2 (https=) |
| KR (2) | KR102777127B1 (https=) |
| CN (3) | CN118085091A (https=) |
| AU (2) | AU2017325654B2 (https=) |
| BR (1) | BR112019001989A2 (https=) |
| CA (1) | CA3032820A1 (https=) |
| CL (3) | CL2019000261A1 (https=) |
| CO (1) | CO2019000931A2 (https=) |
| DK (1) | DK3494134T3 (https=) |
| ES (1) | ES3062797T3 (https=) |
| FI (1) | FI3494134T3 (https=) |
| HR (1) | HRP20260151T1 (https=) |
| IL (2) | IL315729A (https=) |
| LT (1) | LT3494134T (https=) |
| MX (1) | MX2019001458A (https=) |
| NZ (1) | NZ750257A (https=) |
| PT (1) | PT3494134T (https=) |
| SG (1) | SG11201900616UA (https=) |
| SI (1) | SI3494134T1 (https=) |
| WO (1) | WO2018052556A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013008697A2 (pt) | 2010-09-24 | 2016-06-21 | Massachusetts Inst Technology | géis nanoestruturados capazes de liberação controlada de agentes encapsulados |
| HRP20260151T1 (hr) | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
| WO2018031258A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| WO2018031400A1 (en) * | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| US11020410B2 (en) | 2017-02-03 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof |
| EP3710482A4 (en) * | 2017-11-14 | 2021-08-18 | University Of Virginia Patent Foundation | COMPOSITIONS AND METHODS OF MANUFACTURING AND USING BISPECIFIC ANTIBODIES |
| IL276286B2 (en) * | 2018-01-26 | 2025-07-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
| CN112543643A (zh) * | 2018-03-05 | 2021-03-23 | 肿瘤免疫股份有限公司 | 使用可溶性cd24用于治疗获得性免疫缺陷综合征（hiv/aids）的方法 |
| JP2021520352A (ja) | 2018-04-04 | 2021-08-19 | アリヴィオ セラピューティクス， インコーポレイテッド | 生物製剤の制御送達用の自己組織化ゲルおよびその製造方法 |
| WO2019235426A1 (ja) * | 2018-06-04 | 2019-12-12 | 中外製薬株式会社 | 細胞質内での半減期が変化した抗原結合分子 |
| WO2020051507A1 (en) | 2018-09-06 | 2020-03-12 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
| JP7410143B2 (ja) * | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | 二重特異性抗体及びその用途 |
| EP3883968A4 (en) * | 2018-11-22 | 2022-08-17 | Agency for Science, Technology and Research | MODIFIED FC REGION |
| SG11202104352XA (en) * | 2018-12-18 | 2021-05-28 | Boehringer Ingelheim Io Canada Inc | Flt3 agonist antibodies and uses thereof |
| AR117453A1 (es) * | 2018-12-20 | 2021-08-04 | Genentech Inc | Fc de anticuerpos modificados y métodos para utilizarlas |
| CN111978393B (zh) * | 2019-05-23 | 2024-06-18 | 厦门大学 | 抗乙肝病毒新型抗体及其用途 |
| MY210065A (en) | 2019-06-17 | 2025-08-25 | Visterra Inc | Humanized antibody molecules to cd138 and uses thereof |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| EP4025596A4 (en) * | 2019-09-04 | 2023-09-20 | Cedars-Sinai Medical Center | Use of calcineurin inhibitor free ctla4-ig + anti-il6/il6r for long term immunosuppression in solid organ transplant recipients |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| WO2021119467A1 (en) | 2019-12-11 | 2021-06-17 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| CN111254207A (zh) * | 2020-01-22 | 2020-06-09 | 郑州大学第一附属医院 | 用于区别自身免疫性肝炎和健康人群的肠道微生物标志物及其应用 |
| CA3187823A1 (en) | 2020-06-24 | 2021-12-30 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| US12098178B2 (en) | 2020-12-04 | 2024-09-24 | Visterra, Inc. | Methods of using interleukin-2 agents |
| CA3173944A1 (en) | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| TW202245825A (zh) | 2021-01-20 | 2022-12-01 | 美商威特拉公司 | 介白素-2藥劑及其用途 |
| EP4297796A1 (en) * | 2021-02-25 | 2024-01-03 | Cidara Therapeutics, Inc. | Variant fc domains and uses thereof |
| TW202246339A (zh) * | 2021-03-03 | 2022-12-01 | 愛爾蘭商赫萊森治療愛爾蘭公司 | 治療甲狀腺眼疾的方法 |
| WO2023097254A1 (en) | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
| AU2022399832A1 (en) | 2021-12-01 | 2024-06-06 | The Children's Hospital Of Philadelphia | Methods of using interleukin-2 agents |
| CA3243493A1 (en) | 2022-02-11 | 2023-08-17 | Visterra, Inc. | INTERLEUKIN-2 MUTEINS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| US20240092921A1 (en) | 2022-04-25 | 2024-03-21 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| CN115028738B (zh) * | 2022-06-14 | 2025-05-16 | 天津医科大学 | 一种Fc融合蛋白双重靶向降解剂及应用 |
| WO2024027793A1 (en) * | 2022-08-05 | 2024-02-08 | I-Mab Biopharma (Hangzhou) Co., Ltd. | Bispecific antibodies targeting ifnar1 and blys |
| JP2025534759A (ja) * | 2022-10-18 | 2025-10-17 | クロスポイント セラピューティクス インコーポレイテッド | ヒト抗体ｆｃドメイン変異体及びその用途 |
| US20240150447A1 (en) * | 2022-11-04 | 2024-05-09 | Cephalon, LLC | Compositions and methods for increasing transport into the brain |
| EP4680649A1 (en) * | 2023-03-06 | 2026-01-21 | Joint Stock Company "Biocad" | Antibody-like molecule comprising heterodimer of human cd1b (cluster of differentiation 1) protein |
| WO2024211779A1 (en) * | 2023-04-05 | 2024-10-10 | The Regents Of The University Of California | Affinity peptides for diagnosis and treatment of viral infections |
| CN120060370A (zh) * | 2023-11-29 | 2025-05-30 | 上海科锐克医药科技有限公司 | 用于递送人vegf受体融合蛋白的基因递送载体及其应用 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2025221954A1 (en) | 2024-04-17 | 2025-10-23 | Visterra, Inc. | Use of il-2 variant for treating kidney transplant rejection |
| WO2026039779A1 (en) | 2024-08-15 | 2026-02-19 | Yale University | Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5843708A (en) | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1572091A4 (en) | 2002-07-09 | 2008-03-05 | Genentech Inc | COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| AU2012203476A1 (en) * | 2003-11-12 | 2012-07-05 | Biogen Idec Ma Inc. | Neonatal Fc Receptor (FcRn)-Binding Polypeptide Variants, Dimeric Fc Binding Proteins and Methods Related Thereto |
| SI1706424T1 (sl) | 2004-01-12 | 2010-01-29 | Applied Molecular Evolution | Variante fc regij |
| AU2005274905B2 (en) | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| AU2005285347A1 (en) * | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US8546543B2 (en) * | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1858925A2 (en) * | 2005-01-12 | 2007-11-28 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| US20110123440A1 (en) | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| WO2008030564A2 (en) | 2006-09-08 | 2008-03-13 | Verenium Corporation | Aglycosylated antibodies and methods of making and using those antibodies |
| WO2008032833A1 (en) | 2006-09-14 | 2008-03-20 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
| WO2008114011A2 (en) * | 2007-03-19 | 2008-09-25 | Medimmune Limited | Fc polypeptide variants obtained by ribosome display methodology |
| HRP20150279T1 (hr) | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc inaäśice s promijenjenim vezanjem na fcrn |
| JP5913980B2 (ja) * | 2008-10-14 | 2016-05-11 | ジェネンテック， インコーポレイテッド | 免疫グロブリン変異体及びその用途 |
| WO2010068722A1 (en) * | 2008-12-12 | 2010-06-17 | Medimmune, Llc | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
| JP2012515556A (ja) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| AU2015200990B2 (en) | 2009-03-20 | 2016-07-21 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Optimized Fc variants |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| EP2711018A1 (en) | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| US9013699B2 (en) | 2009-11-09 | 2015-04-21 | Cantwell G. Carson | Vaccine testing system |
| EP4012714A1 (en) | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| US20170039314A1 (en) | 2010-03-23 | 2017-02-09 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| WO2012032080A1 (en) * | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
| EP2647706B1 (en) * | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| US9505826B2 (en) | 2010-12-22 | 2016-11-29 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
| US8952132B2 (en) | 2011-02-07 | 2015-02-10 | Research Development Foundation | Engineered immunoglobulin FC polypeptides |
| WO2012132067A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| AU2012233313C1 (en) | 2011-03-30 | 2017-08-03 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
| MX2018012383A (es) | 2011-03-30 | 2023-03-07 | Chugai Pharmaceutical Co Ltd | Método para alterar la retención en plasma e inmunogenicidad de la molécula de union al antígeno. |
| WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| EP2752200B1 (en) | 2011-09-30 | 2023-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule inducing immune response to target antigen |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| RU2014117505A (ru) | 2011-09-30 | 2015-11-10 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула для ускорения удаления антигенов |
| KR20230143201A (ko) | 2011-11-30 | 2023-10-11 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| JP6313712B2 (ja) | 2011-12-21 | 2018-04-18 | アムジエン・インコーポレーテツド | 新生児Ｆｃ受容体への結合を強化された変異型Ｆｃポリペプチド |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| KR102148303B1 (ko) * | 2012-02-11 | 2020-08-26 | 제넨테크, 인크. | R-스폰딘 전위 및 그의 사용 방법 |
| EP3738980A1 (en) | 2012-02-24 | 2020-11-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc gamma riib |
| US10011660B2 (en) | 2012-04-30 | 2018-07-03 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| WO2013180200A1 (ja) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
| EP2857419B1 (en) | 2012-05-30 | 2021-01-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| JP6280300B2 (ja) | 2012-08-24 | 2018-02-14 | 中外製薬株式会社 | 脳疾患治療剤 |
| US20140294812A1 (en) | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| UA118029C2 (uk) * | 2013-04-29 | 2018-11-12 | Ф. Хоффманн-Ля Рош Аг | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування |
| ES2869459T3 (es) * | 2014-05-16 | 2021-10-25 | Medimmune Llc | Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas |
| KR20170015920A (ko) | 2014-06-12 | 2017-02-10 | 에프. 호프만-라 로슈 아게 | ＦｃＲｎ 상호작용이 변화된 항체를 선별하는 방법 |
| FR3024453B1 (fr) | 2014-08-01 | 2018-06-29 | Lab Francais Du Fractionnement | Procede de production de variants ayant un fc presentant une sialylation amelioree |
| DK3215528T3 (da) * | 2014-11-06 | 2019-10-07 | Hoffmann La Roche | Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder |
| KR20180002653A (ko) * | 2015-04-07 | 2018-01-08 | 제넨테크, 인크. | 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법 |
| FR3035879B1 (fr) | 2015-05-07 | 2025-02-28 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
| EP3423572B1 (en) | 2016-03-02 | 2023-11-29 | Momenta Pharmaceuticals, Inc. | Methods related to engineered fc constructs |
| CA3011887C (en) | 2016-03-14 | 2024-10-29 | Universitetet I Oslo | Genetically transformed immunoglobulins with altered FCRN binding |
| US20170298119A1 (en) * | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
| HRP20260151T1 (hr) | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
| EP4424707A3 (en) | 2017-09-19 | 2024-11-13 | Tillotts Pharma AG | Antibody variants |
-
2017
- 2017-08-02 HR HRP20260151TT patent/HRP20260151T1/hr unknown
- 2017-08-02 ES ES17754535T patent/ES3062797T3/es active Active
- 2017-08-02 FI FIEP17754535.7T patent/FI3494134T3/fi active
- 2017-08-02 IL IL315729A patent/IL315729A/en unknown
- 2017-08-02 BR BR112019001989-8A patent/BR112019001989A2/pt unknown
- 2017-08-02 EP EP17754535.7A patent/EP3494134B1/en active Active
- 2017-08-02 KR KR1020197006298A patent/KR102777127B1/ko active Active
- 2017-08-02 PT PT177545357T patent/PT3494134T/pt unknown
- 2017-08-02 US US15/667,309 patent/US11858980B2/en active Active
- 2017-08-02 JP JP2019505188A patent/JP7464389B2/ja active Active
- 2017-08-02 CN CN202410254572.6A patent/CN118085091A/zh active Pending
- 2017-08-02 AU AU2017325654A patent/AU2017325654B2/en active Active
- 2017-08-02 IL IL264590A patent/IL264590B2/en unknown
- 2017-08-02 CN CN202410254540.6A patent/CN118388638A/zh active Pending
- 2017-08-02 SI SI201731655T patent/SI3494134T1/sl unknown
- 2017-08-02 LT LTEPPCT/US2017/045126T patent/LT3494134T/lt unknown
- 2017-08-02 CN CN201780059776.2A patent/CN110072887A/zh active Pending
- 2017-08-02 NZ NZ750257A patent/NZ750257A/en unknown
- 2017-08-02 KR KR1020257006561A patent/KR20250036943A/ko active Pending
- 2017-08-02 WO PCT/US2017/045126 patent/WO2018052556A1/en not_active Ceased
- 2017-08-02 DK DK17754535.7T patent/DK3494134T3/da active
- 2017-08-02 SG SG11201900616UA patent/SG11201900616UA/en unknown
- 2017-08-02 CA CA3032820A patent/CA3032820A1/en active Pending
- 2017-08-02 MX MX2019001458A patent/MX2019001458A/es unknown
-
2019
- 2019-01-30 CO CONC2019/0000931A patent/CO2019000931A2/es unknown
- 2019-01-31 CL CL2019000261A patent/CL2019000261A1/es unknown
-
2020
- 2020-04-10 US US16/845,894 patent/US20200277358A1/en not_active Abandoned
-
2022
- 2022-01-06 CL CL2022000036A patent/CL2022000036A1/es unknown
- 2022-06-14 JP JP2022096036A patent/JP2022120132A/ja not_active Withdrawn
-
2024
- 2024-10-23 CL CL2024003234A patent/CL2024003234A1/es unknown
- 2024-12-03 AU AU2024270619A patent/AU2024270619A1/en active Pending
-
2025
- 2025-06-04 US US19/227,822 patent/US20250296982A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531705A5 (https=) | ||
| DK2805969T3 (en) | Optimized Fc variants | |
| CN104508133B (zh) | 用于产生单体和多聚体分子的方法及其用途 | |
| US10093714B1 (en) | Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof | |
| RU2675319C2 (ru) | РАЗРАБОТКА СТАБИЛЬНОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В ДОМЕНЕ Fc | |
| EP3061770B1 (en) | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects | |
| Monnet et al. | Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions | |
| CN115667305A (zh) | 修饰的免疫球蛋白fc区 | |
| CN114466663B (zh) | 以FcRn拮抗剂治疗抗体介导的障碍的方法 | |
| RU2016139006A (ru) | Мультимерные fc-белки | |
| CN105026430A (zh) | 工程化免疫球蛋白重链-轻链对及其用途 | |
| CN116059346A (zh) | 抗-肌肉生长抑制因子抗体及使用方法 | |
| JP2021500348A (ja) | 単一特異性抗体から多重特異性抗体を生成させるための方法 | |
| US20230416371A1 (en) | Heterodimer fc polypeptide | |
| CN121057750A (zh) | 结合ox40l的抗体和使用方法 | |
| AU2015200990A1 (en) | Optimized Fc variants | |
| CN115151567A (zh) | 治疗性Fc组合物的化学诱导结合和解离以及T细胞接合器与人血清白蛋白的化学诱导二聚化 | |
| AU2015202560B2 (en) | Method for Making Antibody Fc-Heterodimeric Molecules Using Electrostatic Steering Effects | |
| RU2019104889A (ru) | Генно-инженерные полипептиды и их применение | |
| RU2810540C2 (ru) | РАЗРАБОТКА СТАБИЛЬНОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В ДОМЕНЕ Fc | |
| Jefferis | Fc Protein Engineering | |
| Jefferis | Antibody Fc: Chapter 17. Fc Protein Engineering | |
| AU2016213792A1 (en) | Optimized Fc variants |